Once-Weekly Combo Diabetes Jab Wins EMA Recommendation
Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe. Kyinsu (insulin icodec with semaglutide; Novo Nordisk) received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]
Once-Weekly Combo Diabetes Jab Wins EMA Recommendation Read More »
